### news release

Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40201-1438 http://www.humana.com

#### FOR MORE INFORMATION CONTACT:

Regina Nethery Humana Investor Relations (502) 580-3644 e-mail: Rnethery@humana.com

Tom Noland Humana Corporate Communications (502) 580-3674 e-mail: Tnoland@humana.com



## **Humana Reports Detailed Second Quarter 2007 Financial Results**

- Full year EPS expected to grow more than 50 percent in 2007
- Lower administrative costs primarily from efficiency and productivity gains
- Improving medical expense ratios in both segments
- GAAP cash flows from operations up 33 percent year to date
- Non-GAAP cash flows from operations up 71 percent year to date

**LOUISVILLE, KY** (**July 30, 2007**) – Humana Inc. (NYSE: HUM) today reported financial results for the quarter ended June 30, 2007 (2Q07) including diluted earnings per common share (EPS) of \$1.28, as announced in the company's July 18, 2007 press release. The company earned \$0.53 per share for the quarter ended June 30, 2006 (2Q06). The year-over-year improvement in second quarter results reflected higher operating earnings in both of the company's business segments, primarily driven by efficiency gains in its consolidated administrative costs as well as medical expense ratio improvement.

As also announced on July 18, 2007, the company estimates EPS for the year ending December 31, 2007 (FY07E) will be in the range of \$4.40 to \$4.50 versus \$2.90 for the year ended December 31, 2006 (FY06).

"An across-the-board focus on operational excellence led to an extremely strong second quarter," said Michael B. McCallister, Humana's president and chief executive officer. "These same dynamics are expected to fuel Humana's performance for the remainder of the year and position us well for growth into the future."

For the six months ended June 30, 2007 (1H07) the company reported \$1.70 in EPS compared to \$1.03 for the six months ended June 30, 2006 (1H06). Results for 1H06 included approximately \$0.19 per

share of venture capital gains that did not recur in 1H07. The year-over-year increase in 1H07 financial results was primarily due to better operating performance in both business segments.

**Revenues** – 2Q07 consolidated revenues rose 19 percent to \$6.43 billion from \$5.41 billion in 2Q06, with total premium and administrative services fees up 18 percent compared to the prior year's quarter. This year-over-year increase was primarily driven by higher average Medicare membership versus 2Q06.

1H07 consolidated revenues rose 25 percent to \$12.63 billion from \$10.11 billion in 1H06 with total premium and administrative services fees up 25 percent compared to the prior year's period, also primarily driven by higher average enrollment in the company's Medicare plans.

**Medical costs** – The 2Q07 consolidated medical expense ratio (medical expenses as a percent of premium revenues or MER) of 83.4 percent was 170 basis points lower than the 2Q06 MER of 85.1 percent as a result of MER improvement in both the Government and Commercial segments.

The consolidated MER for 1H07 of 85.1 percent was 70 basis points higher than the 1H06 consolidated MER of 84.4 percent, as the year-over-year increase in the Government Segment MER resulting from the Medicare Part D claims pattern outweighed the improvement in the Commercial Segment MER.

Selling, general, & administrative (SG&A) expenses – The 2Q07 consolidated SG&A expense ratio (SG&A expenses as a percent of premiums, administrative services fees and other revenue) decreased 70 basis points to 13.0 percent for 2Q07 from 13.7 percent in 2Q06. The year-over-year decline was primarily the result of improving administrative cost efficiency and productivity gains associated with servicing the company's 11.3 million medical members.

The SG&A expense ratio for 1H07 of 13.2 percent was 160 basis points lower than that for 1H06 of 14.8 percent also primarily driven by efficiency and productivity gains.

### **Government Segment Results Summary**

#### Pretax results:

- Government Segment pretax earnings were \$288.8 million in 2Q07 compared to \$98.0 million in 2Q06. As expected, this primarily reflects a more normal MER pattern for the Part D benefit for 2007 as well as administrative cost efficiency associated with higher average Medicare medical membership. The extended enrollment period for this benefit during 2006 distorted the claims pattern associated with the beneficiaries' progression through the Part D benefit stages in the prior year.
- For 1H07, pretax earnings for the Government Segment of \$306.7 million increased by \$187.1 million, or 157 percent versus 1H06 pretax earnings for the segment of \$119.6 million, primarily reflecting the same factors impacting the year-over-year comparison for the second quarter.

#### **Enrollment:**

Medicare Advantage membership grew to 1,133,700 at June 30, 2007, an increase of 173,900, or 18 percent, from June 30, 2006 and 20,300, or 2 percent, from March 31, 2007. Average Medicare Advantage membership for 2Q07 was up 28 percent compared to that for 2Q06. The

- company's expanded participation in various Medicare products and markets combined with the company's increased sales and marketing efforts for these programs led to the higher membership level both year over year and sequentially.
- Membership in the company's stand-alone Prescription Drug Plans (PDPs) totaled 3,440,100 at June 30, 2007 compared to 3,458,800 at June 30, 2006 and 3,473,700 at March 31, 2007. Average stand-alone PDP membership was 21 percent higher in 2Q07 than 2Q06.
- TRICARE membership of 2,868,200 at June 30, 2007 was essentially unchanged from both June 30, 2006 and March 31, 2007.
- Medicaid membership of 567,600 at June 30, 2007 increased 149,100 from June 30, 2006 due
  primarily to the award of a new Puerto Rico regional ASO contract during the fourth quarter of
  2006, partially offset by eligible Puerto Rico Medicaid members choosing to move into the
  Medicare Advantage program.

### Premiums and administrative services fees:

- Medicare Advantage premiums of \$2.80 billion in 2Q07 increased 33 percent compared to \$2.11 billion in 2Q06, primarily the result of higher average membership.
- Medicare stand-alone Part D premiums of \$1.05 billion in 2Q07 increased 31 percent compared to \$801.8 million in 2Q06, primarily the result of higher average membership.
- TRICARE premiums and administrative services fees during 2Q07 increased \$71.8 million to \$740.6 million compared to \$668.8 million in 2Q06.

### Medical Expenses:

• The Government Segment MER decreased 170 basis points to 84.3 percent in 2Q07 compared to 86.0 percent in the prior year's quarter. This decrease reflects a more normalized MER pattern for the Medicare Part D benefit for 2007. The extended enrollment period for this benefit during the prior year distorted the claims pattern associated with the beneficiaries' progression through the Part D benefit stages in 2006.

### SG&A Expenses:

• The Government Segment's SG&A expense ratio for 2Q07 of 10.0 percent was 150 basis points lower than that for 2Q06 of 11.5 percent primarily driven by efficiency and productivity gains associated with servicing higher average Medicare membership. The 2Q07 SG&A expense ratio was approximately 30 basis points lower than previously expected primarily due to improving staffing metrics and enhanced processes associated with servicing its Medicare business.

### **Commercial Segment Results Summary**

#### Pretax results:

- Commercial Segment pretax earnings were \$50.8 million in 2Q07 compared to \$42.3 million in 2Q06. Commercial Segment operating earnings in 2Q07 continue to reflect the company's commitment to underwriting discipline and strategic growth in select lines of business.
- For 1H07, pretax earnings for the Commercial Segment of \$145.2 million were \$6.8 million, or 5 percent lower than 1H06 pretax earnings for the segment of \$152.0 million as a result of a \$45.3 million pretax gain associated with the sale of a venture capital investment that occurred in 1Q06.

#### Enrollment:

- Commercial Segment medical membership of 3,278,700 at June 30, 2007 was essentially unchanged from both June 30, 2006 and March 31, 2007.
- Membership in the company's Smart plans and other consumer offerings grew to 480,900 at June 30, 2007, an increase of 64,500, or 15 percent, from June 30, 2006 and 9,600, or 2 percent, from March 31, 2007. Medical members in these products comprise approximately 15 percent of Commercial medical membership at June 30, 2007 and March 31, 2007 compared to 13 percent at June 30, 2006.

### Premiums and administrative services fees:

- Premiums and administrative services fees for the Commercial Segment decreased 3 percent to \$1.59 billion in 2Q07 compared to \$1.64 billion in the prior year's quarter, primarily due to lower average commercial fully-insured membership, down 8 percent year over year, as well as a shift in business mix from fully-insured to ASO enrollment.
- Commercial Segment medical premiums for fully-insured groups increased approximately 5 percent on a per-member basis during 2Q07 compared to 2Q06.

### Medical Expenses:

• In 2Q07, the Commercial Segment MER of 80.7 percent was 220 basis points lower than the 2Q06 MER of 82.9 percent, primarily reflecting improving medical cost utilization trends and the company's continued commitment to underwriting discipline.

### SG&A Expenses:

• The Commercial Segment SG&A expense ratio of 21.8 percent for 2Q07 compares to 18.7 percent in 2Q06, primarily the combined result of higher average ASO membership and administrative costs associated with increased business for the company's mail order pharmacy. Average ASO membership increased 8 percent versus the prior year's quarter.

### **Balance Sheet**

- Cash and cash equivalents of \$3.72 billion increased \$26.7 million or 1 percent sequentially. The
  early receipt of the April Medicare premium from the Centers for Medicare and Medicaid
  Services (CMS) during 1Q07 was essentially offset by the early receipt of the July Medicare
  premium from CMS during 2Q07.
- Parent company cash and investments decreased to \$419.3 million at June 30, 2007 from \$424.4 million at December 31, 2006.
- Unearned revenues of \$1.36 billion increased 2 percent from the March 31, 2007 balance of \$1.33 billion also due to the timing of the receipts of Medicare premiums from CMS.
- Debt-to-total capitalization at June 30, 2007 was 26.1 percent, down 350 basis points from March 31, 2007 due primarily to the repayment of 1Q07 borrowings against the company's credit facility.
- The company's working capital at June 30, 2007 included approximately \$690.2 million in net Part D risk-share payables to CMS associated with the company's Medicare Advantage and

- stand-alone PDP offerings. Approximately \$728.1 million of this net liability related to Part D plan offerings for the year ended December 31, 2006.
- Days in claims payable excluding the impact of Medicare stand-alone PDPs were up slightly to 62.4 days at June 30, 2007 from 62.0 days at March 31, 2007.

### **Cash Flows from Operations**

Cash flows provided by operations for 2Q07 of \$477.3 million compared to cash provided by operations of \$534.9 million in 2Q06.

Cash flows from operations				
(\$ in millions)	2Q07	2Q06	1H07	1H06
Cash flows provided by operations in				
accordance with Generally Accepted				
Accounting Principles (GAAP)	\$477.3	\$534.9	\$2,051.7	\$1,542.8
Timing of premium payment from CMS <sup>(a)</sup>	(45.6)	(257.2)	(1,175.3)	(1,031.7)
Non-GAAP cash flows provided by				
operations <sup>(a)(b)</sup>	\$431.7	\$277.7	\$876.4	\$511.1

The company also evaluates operating cash flows on a non-GAAP basis<sup>(a)(b)</sup>. Non-GAAP cash flows provided by operations rose to \$431.7 million<sup>(a)(b)</sup> in 2Q07 from \$277.7 million<sup>(a)(b)</sup> in 2Q06 driven primarily by growth in the company's Medicare operations.

#### **Footnotes**

- (a) When reviewing and analyzing Humana's operating cash flows, company management applies the CMS premium payment in each month to match the corresponding disbursements. To do otherwise distorts meaningful analysis of the company's operating cash flow. Therefore, decisions such as management's forecasting and business plans regarding cash flow use this non-GAAP financial measure.
- (b) The company believes that this non-GAAP measure, when presented in conjunction with the comparable GAAP measure, is useful to both management and its investors in analyzing the company's ongoing business and operating performance. Internally, management uses this non-GAAP financial measure as an indicator of business performance, as well as for operational planning and decision making purposes. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.

### **Conference Call & Virtual Slide Presentation**

Humana will host a conference call, as well as a virtual slide presentation, at 9:00 a.m. eastern time today to discuss its financial results for the quarter and the company's expectations for future earnings. A live virtual presentation (audio with slides) may be accessed via Humana's Investor Relations page at www.humana.com. The company suggests web participants sign on approximately 15 minutes in advance of the call. The company also suggests web participants visit the site well in advance of the call to run a system test and to download any free software needed to view the presentation.

All parties interested in the audio-only portion of the conference call are invited to dial 888-625-7430. No password is required. The company suggests participants dial in approximately ten minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive may be accessed via the Historical Webcasts & Presentations section of the Investor Relations page at www.humana.com.

### **Cautionary Statement**

This news release contains statements and earnings guidance points that are forward-looking. The forward-looking items herein are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking items may be significantly impacted by certain risks and uncertainties described in the following documents filed by Humana with the Securities and Exchange Commission

- Form 10-K for the year ended December, 31, 2006,
- Form 10-Q for the quarter ended March 31, 2007,
- Form 8-Ks filed during 2007.

### **About Humana**

Humana Inc., headquartered in Louisville, Kentucky, is one of the nation's largest publicly traded health benefits companies, with approximately 11.3 million medical members. Humana offers a diversified portfolio of health insurance products and related services – through traditional and consumer-choice plans – to employer groups, government-sponsored plans, and individuals.

Over its 46-year history, Humana has consistently seized opportunities to meet changing customer needs. Today, the company is a leader in consumer engagement, providing guidance that leads to lower costs and a better health plan experience throughout its diversified customer portfolio.

More information regarding Humana is available to investors via the Investor Relations page of the company's web site at www.humana.com, including copies of:

- Annual reports to stockholders;
- Securities and Exchange Commission filings;
- Most recent investor conference presentations;
- Quarterly earnings news releases;
- Replay of most recent earnings release conference calls;
- Calendar of events (includes upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors);
- Corporate Governance information.

Guidance Points as of July 30, 2007	For the year ending December 31, 2007 (in accordance with Generally Accepted Accounting Principles)	Comments
Diluted earnings per common share (EPS)	Full year 2007: \$4.40 to \$4.50 3Q07: \$1.45 to \$1.50	
Revenues	Consolidated revenues: \$24.5 billion to \$25.5 billion;	
	Premiums and ASO fees:  Medicare Advantage: \$10.5 billion to \$11.0 billion;  Medicare stand-alone PDPs:  Approximately \$3.5 billion;  TRICARE: Approximately \$3.0 billion;  Commercial: \$6.5 billion to \$7.0 billion;  Investment income: \$290 million to \$300 million;	
	Other revenue: \$150 million to \$155 million	Other revenue primarily relates to revenues associated with the company's mail order pharmacy; related administrative costs are in SG&A expenses
Ending medical membership (fully- insured and ASO	Medicare Advantage: 1,120,000 to 1,130,000;	
combined)	Medicare stand-alone PDPs: 3.4 million to 3.5 million;	
	TRICARE: No material change from prior year;	
	Medicaid: Down approximately 10,000;	
	Commercial: Up approximately 50,000 to 75,000 from prior year	

Guidance Points as of July 30, 2007	For the year ending December 31, 2007 (in accordance with Generally Accepted Accounting Principles)	Comments
Medical costs	Total Medicare products: MER in the range of 82.5% to 83.5%;	Medicare Advantage and stand- alone PDP combined
	Commercial fully-insured groups:  Medical cost trends in the range of 4.5% to 5.0%; premium yields in line with medical cost trends	2007 secular Commercial medical cost trend components as follows: inpatient hospital utilization – flat to 1 percent; inpatient and outpatient hospital rates – mid to upper single digits; outpatient hospital utilization – low to mid single digits; physician – mid single digits; and pharmacy – low double digits.
Selling, general & administrative expenses	Consolidated SG&A expense ratio of 13% to 14%	SG&A expenses as a percent of premiums, administrative costs, and other revenue
Depreciation & amortization	Approximately \$185 million	
Interest expense	Approximately \$70 million	
Pretax results	Total Medicare products: Approximately 5% pretax margin; TRICARE: Approximately 3.5% pretax	Medicare Advantage and stand- alone PDP combined
	margin;	
	Commercial Segment: \$230 million to \$240 million	Includes no material benefit from venture capital gains
Cash flows from operations	\$1.2 billion to \$1.5 billion	Includes accrual for estimated 2007 Part D risk-share payable in the range of zero to \$200 million
Capital expenditures	Approximately \$220 million	
Effective tax rate	Approximately 36% to 37%	
Shares used in computing EPS	Approximately 171 million	

Humana Inc.
Statistical Schedules
And
Supplementary Information
2Q07 Earnings Release

# Humana Inc. Statistical Schedules and Supplementary Information 2Q07 Earnings Release

# Contents

<u>Page</u>	<u>Description</u>
S-3-4	Consolidated Statements of Income
S-5	Consolidated Balance Sheets
S-6-7	Consolidated Statements of Cash Flows
S-8	Key Income Statement Ratios and Segment Operating Results
S-9	Membership Detail
S-10-11	Premiums and Administrative Services Fees Detail
S-12	Percentage of Ending Membership under Capitation Arrangements
S-13-15	Medical Claims Reserves
S-16	Footnotes

# Consolidated Statements of Income

In thousands, except per common share results

	1111 CC 111011111 Z11	404.00,		
			Dollar	Percentage
	2007	2006	Change	Change
Revenues:				
Premiums	\$6,223,250	\$5,264,475	\$958,775	18.2%
Administrative services fees	97,093	83,711	13,382	16.0%
Investment income	72,052	50,567	21,485	42.5%
Other revenue	34,402	8,416	25,986	308.8%
Total revenues	6,426,797	5,407,169	1,019,628	18.9%
Operating expenses:				
Medical	5,190,418	4,479,501	710,917	15.9%
Selling, general and administrative	826,459	733,863	92,596	12.6%
Depreciation	48,820	31,613	17,207	54.4%
Other intangible amortization	5,444	4,983	461	9.3%
Total operating expenses	6,071,141	5,249,960	821,181	15.6%
Income from operations	355,656	157,209	198,447	126.2%
Interest expense	16,066	16,887	(821)	-4.9%
Income before income taxes	339,590	140,322	199,268	142.0%
Provision for income taxes	122,744	50,833	71,911	141.5%
Net income	\$216,846	\$89,489	\$127,357	142.3%
Basic earnings per common share	\$1.30	\$0.55	\$0.75	136.4%
Diluted earnings per common share	\$1.28	\$0.53	\$0.75	141.5%
Shares used in computing basic earnings per common share	166,614	163,706		
Shares used in computing diluted earnings per common share	169,596	167,536		

Three Months Ended June 30,

# Consolidated Statements of Income

In thousands, except per common share results

	Six Months Ended June 30,			
			Dollar	Percentage
	2007	2006	Change	Change
Revenues:				
Premiums	\$12,227,813	\$9,785,961	\$2,441,852	25.0%
Administrative services fees	192,957	162,389	30,568	18.8%
Investment income	145,579	149,469	(3,890)	-2.6%
Other revenue	65,261	13,715	51,546	375.8%
Total revenues	12,631,610	10,111,534	2,520,076	24.9%
Operating expenses:				
Medical	10,404,418	8,263,427	2,140,991	25.9%
Selling, general and administrative	1,647,069	1,474,749	172,320	11.7%
Depreciation	84,329	61,465	22,864	37.2%
Other intangible amortization	9,999	10,037	(38)	-0.4%
Total operating expenses	12,145,815	9,809,678	2,336,137	23.8%
Income from operations	485,795	301,856	183,939	60.9%
Interest expense	33,984	30,326	3,658	12.1%
Income before income taxes	451,811	271,530	180,281	66.4%
Provision for income taxes	163,724	98,326	65,398	66.5%
Net income	\$288,087	\$173,204	\$114,883	66.3%
Basic earnings per common share	\$1.73	\$1.06	\$0.67	63.2%
Diluted earnings per common share	\$1.70	\$1.03	\$0.67	65.0%
Shares used in computing basic earnings per common share	166,213	163,411		
Shares used in computing diluted earnings per common share	169,276	167,430		

# Consolidated Balance Sheets Dollars in thousands, except share amounts

Dollars in thousands, except share amounts					
	June 30,	March 31,	December 31,	Sequential	Change
	2007	2007	2006	Dollar	Percent
Assets					
Current assets:					
Cash and cash equivalents	\$3,720,769	\$3,694,059	\$1,740,304		
Investment securities	3,323,536	3,154,920	3,192,273		
Receivables, net:	, ,				
Premiums	685,479	826,314	667,657		
Administrative services fees	12,074	10,806	13,284		
Securities lending collateral	1,346,065	1,049,195	627,990		
Other	1,318,003	1,135,298	1,091,465		
Total current assets	10,405,926	9,870,592	7,332,973	\$535,334	5.4%
Property and equipment, net	569,412	571,405	545,004	******	, .
Other assets:		211,100	- 1-,1		
Long-term investment securities	400,775	380,138	414,877		
Goodwill	1,330,585	1,331,418	1,310,631		
Other	628,267	552,572	524,011		
Total other assets	2,359,627	2,264,128	2,249,519		
Total assets	\$13,334,965	\$12,706,125	\$10,127,496	\$628,840	4.9%
Total assets	ψ10,00 <del>-1</del> ,000	Ψ12,700,120	Ψ10,121,400	ψ020,040	4.070
Liabilities and Stockholders' Equity					
Liabilities and Stockholders' Equity Current liabilities:					
Medical and other expenses payable	\$2,954,146	\$2,886,214	\$2,488,261		
Trade accounts payable and accrued expenses	2,084,463	1,977,465	1,626,658		
Book overdraft	* *		293,605		
	289,646	284,572	,		
Securities lending payable	1,346,065	1,049,195	627,990		
Unearned revenues	1,355,017	1,330,325	155,298	<b>\$504.500</b>	0.70/
Total current liabilities	8,029,337	7,527,771	5,191,812	\$501,566	6.7%
Long-term debt	1,189,570	1,329,334	1,269,100		
Other long-term liabilities	740,560	689,493	612,698		
Total liabilities	9,959,467	9,546,598	7,073,610	\$412,869	4.3%
Commitments and contingencies					
Stockholders' equity:					
Preferred stock, \$1 par; 10,000,000 shares authorized, none issued	-	-	-		
Common stock, \$0.16 2/3 par; 300,000,000 shares authorized;					
185,002,041 issued at June 30, 2007	30,833	30,746	30,491		
Capital in excess of par value	1,422,370	1,393,582	1,357,077		
Retained earnings	2,197,185	1,980,339	1,909,098		
Accumulated other comprehensive loss	(38,112)	(8,378)	(13,205)		
Treasury stock, at cost, 16,439,317 shares at June 30, 2007	(236,778)	(236,762)	(229,575)		
Total stockholders' equity	3,375,498	3,159,527	3,053,886	\$215,971	6.8%
Total liabilities and stockholders' equity	\$13,334,965	\$12,706,125	\$10,127,496	\$628,840	4.9%
Debt-to-total capitalization ratio	26.1%	29.6%	29.4%		

# Consolidated Statements of Cash Flows

Dollars in thousands

		<u>,</u>	Dollar	Percentage
	2007	2006	Change	Change
Cash flows from operating activities				
Net income Adjustments to reconcile net income to net cash provided by operating activities:	\$216,846	\$89,489		
Depreciation and amortization	54,264	36,596		
Stock-based compensation	10,462	8,471		
(Benefit) provision for deferred income taxes	(17,900)	2,479		
Changes in operating assets and liabilities excluding		,		
the effects of acquisitions:				
Receivables	139,567	3,104		
Other assets	(107,522)	(174,050)		
Medical and other expenses payable	67,932	266,956		
Other liabilities	75,771	57,967		
Unearned revenues	24,692	244,661		
Other	13,154	(818)		
Net cash provided by operating activities	477,266	534,855	(\$57,589)	-10.8%
Cash flows from investing activities				
Acquisitions, net of cash acquired	(224)	(25,818)		
Purchases of property and equipment	(43,973)	(36,712)		
Proceeds from sales of property and equipment	2	18		
Purchases of investment securities	(908,244)	(594,890)		
Proceeds from maturities of investment securities	212,471	100,289		
Proceeds from sales of investment securities	444,692	152,855		
Change in securities lending collateral	(296,870)	9,473		
Net cash used in investing activities	(592,146)	(394,785)	(\$197,361)	-50.0%
Cash flows from financing activities				
Receipts from CMS contract deposits	639,722	550,868		
Withdrawals from CMS contract deposits	(708,277)	(462,981)		
Borrowings under credit agreement	400,000	-		
Repayments under credit agreement	(510,000)	(300,000)		
Proceeds from issuance of senior notes	-	498,545		
Debt issue costs	-	(3,825)		
Change in book overdraft	5,074	(3,763)		
Change in securities lending payable	296,870	(9,473)		
Common stock repurchases	(16)	(4,832)		
Tax benefit from stock-based compensation	5,426	5,252		
Proceeds from stock option exercises and other	12,791	5,198		
Net cash provided by financing activities	141,590	274,989	(\$133,399)	-48.5%
Increase in cash and cash equivalents	26,710	415,059		
Cash and cash equivalents at beginning of period	3,694,059	1,843,405		
Cash and cash equivalents at end of period	\$3,720,769	\$2,258,464		

Three Months Ended June 30,

# Consolidated Statements of Cash Flows

Dollars in thousands

Cash flows from operating activities   Net income   S288,087   \$173,204		2007	2006	Dollar	Percentage
Net income	Cash flows from operating activities	2007	2006	Change	Change
Adjustments to reconcile net income to net cash provided by operating activities:  Depreciation and amortization  Stock-based compensation  Stock-based compensation  Changes in operating assets and liabilities excluding the effects of acquisitions:  Receivables  (124,011)  Changes in operating assets and liabilities excluding the effects of acquisitions:  Receivables  (126,467)  Other assets  (126,467)  Other assets  (126,467)  Other liabilities  134,423  172,719  Unearmed revenues  Other 16,131  (57,778)  Net cash provided by operating activities  Acquisitions, net of cash acquired  Purchases of property and equipment  Proceeds from sales of property and equipment  Proceeds from sales of investment securities  1,873,295)  Receipts from CMS contract deposits  (1,832,365)  Cash flows from financing activities  Receipts from CMS contract deposits  (1,832,389)  Receipts from CMS contract deposits  (1,223,382)  (1,83,359)  (1,818,105)  Repayments under credit agreement  710,000  Rep		\$288.087	\$173.204		
Stock-based compensation   20,264   15,051     Benefit for deferred income taxes   (24,011)   (1,226)     Changes in operating assets and liabilities excluding the effects of acquisitions:   (16,612)   (42,957)     Chief assets   (126,467)   (359,300)     Medical and other expenses payable   465,885   526,763     Other liabilities   134,423   1772,719     Unearmed revenues   1,199,719   1,044,850     Other   16,131   (57,778)     Net cash provided by operating activities   2,051,747   1,542,828   \$508,919   33.0%     Cash flows from investing activities   (27,005)   (25,931)     Purchases of property and equipment   (114,717)   (81,973)     Proceeds from sales of property and equipment   (1873,295)   (2,258,548)     Proceeds from sales of investment securities   769,956   1,010,397     Proceeds from sales of investment securities   926,603   712,685     Change in securities lending collateral   (718,075)   (193,239)     Net cash used in investing activities   (1,032,461)   (834,453)   (\$198,008)   -23.7%     Cash flows from financing activities   (1,233,982)   (736,425)     Borrowings under credit agreement   (760,000)   (300,000)     Repayments under credit agreement   (760,000)   (300,000)     Repayments under credit agreement   (760,000)   (300,000)     Proceeds from issuance of senior notes   498,545     Debt issue costs   (3,259)   (8,181)     Change in socurities lending payable   718,075   193,239     Common stock repurchases   (7,203)   (4,937)     Tax benefit from stock-based compensation   14,554   13,666     Proceeds from stock option exercises and other   30,335   20,939     Net cash and cash equivalents   1,980,465   1,526,448     Cash and cash equivalents   1,980,465   1,526,44	Adjustments to reconcile net income to net cash provided	<b>4</b> _55,551	*		
Benefit for deferred income taxes	Depreciation and amortization	94,328	71,502		
Changes in operating assets and liabilities excluding the effects of acquisitions:  Receivables  Other assets  (126,467) (359,300)  Medical and other expenses payable  Other liabilities  134,423 172,719  Unearned revenues  Other  Unearned revenues  Other  1,199,719 1,044,850  Other  Net cash provided by operating activities  Acquisitions, net of cash acquired  Purchases of property and equipment  Purchases of property and equipment  Purchases of investment securities  Proceeds from sales of property and equipment  Purchases of investment securities  Proceeds from sales of investment securities  Proceeds from sales of investment securities  Cash flows from sales of investment securities  Proceeds from sales of Securities  Cash flows from financing activities  Receipts from CMS contract deposits  (1,032,461) (834,453) (\$198,008) -23.7%  Cash flows from CMS contract deposits  1,483,359 (1,045,062  Withdrawals from CMS contract deposits  1,189,365  Borrowings under credit agreement  710,000 (300,000)  Proceeds from issuance of senior notes  - 498,545  Debt issue costs  - (3,825)  Change in book overfaft  (3,959) (8,181)  Change in book overfaft  (3,959) (8,181)  Change in book overfaft  Proceeds from stock option exercises and other  Proc	Stock-based compensation	20,264	15,051		
the effects of acquisitions: Receivables Receivables (16,612) (42,957) Cibre assets (128,467) (359,300) Medical and other expenses payable A65,885 526,763 Cibre liabilities 1134,423 172,719 Librard revenues (1,199,719) 1,044,850 Cibre Other 16,131 (57,778) Net cash provided by operating activities Acquisitions, net of cash acquired Acquisitions, net of cash acquired Acquisitions, net of seash acquired Acquisitions activities Acquisitions acquisitions activities Acquisit	Benefit for deferred income taxes	(24,011)	(1,226)		
Receivables	Changes in operating assets and liabilities excluding				
Other assets         (126,467)         (359,300)           Medical and other expenses payable         465,885         526,763           Other liabilities         134,423         172,719           Unearmed revenues         1,199,719         1,044,850           Other         16,131         (57,778)           Net cash provided by operating activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         (27,005)         (25,931)         (25,931)         (27,005)         (25,931)         (25,931)         (27,005)         (25,931)         (25,931)         (27,005)         (25,931)         (27,005)         (25,931)         (27,005)         (25,931)         (25,931)         (25,931)         (27,005)         (25,931) <td>the effects of acquisitions:</td> <td></td> <td></td> <td></td> <td></td>	the effects of acquisitions:				
Medical and other expenses payable         465,885         526,763           Other liabilities         134,423         172,719           Unearmed revenues         1,199,719         1,044,850           Other         16,131         (57,778)           Net cash provided by operating activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         (27,005)         (25,931) <td>Receivables</td> <td>(16,612)</td> <td>(42,957)</td> <td></td> <td></td>	Receivables	(16,612)	(42,957)		
Other liabilities         134,423         172,719           Unearmed revenues         1,199,719         1,044,850           Other         16,131         (57,778)           Net cash provided by operating activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         (27,005)         (25,931)         4,072         2,156         4,072         4,072         2,156         4,072         4,072         4,072         4,072<	Other assets	(126,467)	(359,300)		
Unearmed revenues	Medical and other expenses payable	465,885	526,763		
Other         16,131         (57,778)           Net cash provided by operating activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         (27,005)         (25,931)         (25,931)         (25,931)         (27,005)         (25,931)         (25,931)         (27,005)         (25,931)         (27,005)         (25,931)         (27,005)         (27,003)         (27,00	Other liabilities	134,423	172,719		
Net cash provided by operating activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         2,051,747         1,542,828         \$508,919         33.0%           Cash flows from investing activities         (27,005)         (25,931)         (25,931)           Purchases of property and equipment         (114,717)         (81,973)         (81,973)           Proceeds from sales of property and equipment         4,072         2,156           Purchases of investment securities         (1,873,295)         (2,258,548)           Proceeds from maturities of investment securities         769,956         1,010,397           Proceeds from sales of investment securities         926,603         712,685           Change in securities lending collateral         (718,075)         (193,239)           Net cash used in investing activities         1,483,359         1,045,062           Withdrawals from CMS contract deposits         1,483,359         1,045,062           Withdrawals from CMS contract deposits         1,23,982         (736,425)           Borrowings under credit agreement         (760,000)         (300,000)           Proceeds from issuance of senior notes         -         498,545           Debt issue costs         -         (3,825)	Unearned revenues	1,199,719	1,044,850		
Cash flows from investing activities         (27,005)         (25,931)           Acquisitions, net of cash acquired         (27,005)         (25,931)           Purchases of property and equipment         (114,717)         (81,973)           Proceeds from sales of property and equipment         4,072         2,156           Purchases of investment securities         (1,873,295)         (2,258,548)           Proceeds from maturities of investment securities         769,956         1,010,397           Proceeds from sales of investment securities         926,603         712,685           Change in securities lending collateral         (718,075)         (193,239)           Net cash used in investing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         1,483,359         1,045,062         (\$198,008)         -23.7%           Cash flows from financing activities         1,483,359         1,045,062         (\$198,008)         -23.7%           Cash flows from financing activities         1,483,359         1,045,062         (\$198,008)         -23.7%           Cash flows from financing activities         1,483,359         1,045,062         (\$1,720,000)         (\$1,720,000)         (\$1,720,000)         (\$1,720,000)         (\$1,720,000)         (\$1,720,000)	Other	16,131	(57,778)		
Acquisitions, net of cash acquired  Purchases of property and equipment  Proceeds from sales of property and equipment  Purchases of investment securities  Proceeds from maturities of investment securities  Proceeds from maturities of investment securities  Proceeds from sales of investment securities  Proceeds from financing activities  Proceeds from source deposits  Proceeds from surfact deposits  Proceeds from Source deposits  Proceeds from surfact deposits  Proceeds from issuance of senior notes  Proceeds from issuance of senior notes  Proceeds from securities lending payable  Proceeds from stock repurchases  Proceeds from stock option exercises and other  Proceeds	Net cash provided by operating activities	2,051,747	1,542,828	\$508,919	33.0%
Purchases of property and equipment         (114,717)         (81,973)           Proceeds from sales of property and equipment         4,072         2,156           Purchases of investment securities         (1,873,295)         (2,258,548)           Proceeds from maturities of investment securities         769,956         1,010,397           Proceeds from sales of investment securities         926,603         712,685           Change in securities lending collateral         (718,075)         (193,239)           Net cash used in investing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         1,483,359         1,045,062         (\$198,008)         -23.7%           Cash gradient from financing activities         1,483,359         1,045,062         (\$198,008)         -23.7% </td <td>Cash flows from investing activities</td> <td></td> <td></td> <td></td> <td></td>	Cash flows from investing activities				
Proceeds from sales of property and equipment Purchases of investment securities Proceeds from maturities of investment securities Proceeds from sales of investment securities Proceeds investment securities Proceeds from financing activities Proceeds from CMS contract deposits Proceeds from CMS contract deposits Proceeds from CMS contract deposits Proceeds from issuance of senior notes Proceeds from stock repurchases Proceeds from stock-based compensation Proceeds from stock-based compensation Proceeds from stock-based compensation Proceeds from stock option exercises and other Proceeds from stock option exercises and other Proceeds from stock equivalents Proceeds from sales from from from from from from from from	Acquisitions, net of cash acquired	(27,005)	(25,931)		
Purchases of investment securities Proceeds from maturities of investment securities Proceeds from sales of investment securities Proceeds from cMs contract deposits Proceeds from CMs contract deposits Proceeds from cMs contract deposits Proceeds from issuance of senior notes Proceeds from isour of senior notes Proceeds from sook overdraft Proceeds from stock overdraft Proceeds from stock repurchases Proceeds from stock-based compensation Proceeds from stock-based compensation Proceeds from stock option exercises and other Proceeds	Purchases of property and equipment	(114,717)	(81,973)		
Proceeds from maturities of investment securities Proceeds from sales of investment securities  (718,075) (193,239)  Net cash used in investing activities  Receipts from CMS contract deposits Proceeds from CMS contract deposits Proceeds from CMS contract deposits Proceeds from issuance of senior notes Proceeds from issuance of senior notes Proceeds from issuance of senior notes Proceeds from isourities lending payable Proceeds from stock overdraft Proceeds from stock repurchases Proceeds from stock-based compensation Proceeds from stock option exercises and other Proceeds from stock option exercises and other Proceeds from stock option exercises and other Proceeds from stock and cash equivalents Proceeds from stock option operiod  1,740,304 Proceeds from stock option exercises and cash equivalents Proceeds from stock option operiod  1,740,304 Proceeds from stock option exercises and cash equivalents Proceeds from stock option operiod  1,740,304 Proceeds from stock option exercises and other Proceeds from st	Proceeds from sales of property and equipment	4,072	2,156		
Proceeds from sales of investment securities Change in securities lending collateral  Net cash used in investing activities  (1,032,461)  (834,453)  (\$198,008}  (\$198,008)  (\$198,008}  (\$198,008}  (\$198,008}  (\$198,008}  (\$198,008}  (	Purchases of investment securities	(1,873,295)	(2,258,548)		
Change in securities lending collateral         (718,075)         (193,239)           Net cash used in investing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash quivalents at beginning of period         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash and cash equivalents at beginning of period         (1,045,062)         (1,045,062)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,000)         (10,0	Proceeds from maturities of investment securities	769,956	1,010,397		
Net cash used in investing activities         (1,032,461)         (834,453)         (\$198,008)         -23.7%           Cash flows from financing activities         Receipts from CMS contract deposits         1,483,359         1,045,062           Withdrawals from CMS contract deposits         (1,223,982)         (736,425)           Borrowings under credit agreement         710,000         100,000           Repayments under credit agreement         (760,000)         (300,000)           Proceeds from issuance of senior notes         - 498,545           Debt issue costs         - (3,825)           Change in book overdraft         (3,959)         (8,181)           Change in securities lending payable         718,075         193,239           Common stock repurchases         (7,203)         (4,937)           Tax benefit from stock-based compensation         14,554         13,656           Proceeds from stock option exercises and other         30,335         20,939           Net cash provided by financing activities         961,179         818,073         \$143,106         17.5%           Increase in cash and cash equivalents         1,980,465         1,526,448           Cash and cash equivalents at beginning of period         1,740,304         732,016	Proceeds from sales of investment securities	926,603	712,685		
Cash flows from financing activities  Receipts from CMS contract deposits  Withdrawals from CMS contract deposits  Borrowings under credit agreement  Repayments under credit agreement  Repayments under credit agreement  Proceeds from issuance of senior notes  Debt issue costs  Change in book overdraft  Change in securities lending payable  Common stock repurchases  Tax benefit from stock-based compensation  Proceeds from stock option exercises and other  Net cash provided by financing activities  1,980,465  1,526,448  Cash and cash equivalents at beginning of period  1,740,304  1,740,304  1,045,062  1,045,062  (736,425)  1,045,062  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (736,425)  (740,304  732,016	Change in securities lending collateral	(718,075)	(193,239)		
Receipts from CMS contract deposits	Net cash used in investing activities	(1,032,461)	(834,453)	(\$198,008)	-23.7%
Withdrawals from CMS contract deposits       (1,223,982)       (736,425)         Borrowings under credit agreement       710,000       100,000         Repayments under credit agreement       (760,000)       (300,000)         Proceeds from issuance of senior notes       -       498,545         Debt issue costs       -       (3,825)         Change in book overdraft       (3,959)       (8,181)         Change in securities lending payable       718,075       193,239         Common stock repurchases       (7,203)       (4,937)         Tax benefit from stock-based compensation       14,554       13,656         Proceeds from stock option exercises and other       30,335       20,939         Net cash provided by financing activities       961,179       818,073       \$143,106       17.5%         Increase in cash and cash equivalents       1,980,465       1,526,448         Cash and cash equivalents at beginning of period       1,740,304       732,016	Cash flows from financing activities				
Borrowings under credit agreement Repayments under credit agreement Proceeds from issuance of senior notes Debt issue costs Change in book overdraft Common stock repurchases Common stock option exercises and other Proceeds from stock option exercises and cash equivalents Cash and cash equivalents at beginning of period  710,000 (300,000) (300,000) (490,000) (300,000) (300,000) (300,000) (498,545 (3,959) (8,181) (8,181) (7,203) (8,181) (7,203) (4,937)	Receipts from CMS contract deposits	1,483,359	1,045,062		
Repayments under credit agreement  Proceeds from issuance of senior notes  Debt issue costs  Change in book overdraft  Change in securities lending payable  Common stock repurchases  Tax benefit from stock-based compensation  Proceeds from stock option exercises and other  Net cash provided by financing activities  Procease in cash and cash equivalents  Tax beginning of period  (760,000)  (300,000)  498,545  (3,825)  (8,181)  718,075  193,239  (4,937)  14,554  13,656  20,939  818,073  \$143,106  17.5%	Withdrawals from CMS contract deposits	(1,223,982)	(736,425)		
Proceeds from issuance of senior notes  Debt issue costs  Change in book overdraft  Change in securities lending payable  Common stock repurchases  Tax benefit from stock-based compensation  Proceeds from stock option exercises and other  Net cash provided by financing activities  Procease in cash and cash equivalents  Tax beginning of period  Proceeds from stock option exercises and other  1,980,465  1,526,448  1,740,304  Proceeds from issuance of senior notes  (3,825)  (8,181)  (1,93,239  (4,937)  14,554  13,656  20,939  818,073  \$143,106  17.5%	Borrowings under credit agreement	710,000	100,000		
Debt issue costs Change in book overdraft Change in securities lending payable Change in securities lending payable Common stock repurchases (7,203) Tax benefit from stock-based compensation Proceeds from stock option exercises and other Net cash provided by financing activities  1,980,465  1,526,448 Cash and cash equivalents at beginning of period  1,740,304  1,740,304  1,3825) (8,181) (1,937,239 (4,937) (4,937) (1,93	Repayments under credit agreement	(760,000)	(300,000)		
Change in book overdraft Change in securities lending payable Change in securities lending payable Common stock repurchases (7,203) Tax benefit from stock-based compensation Proceeds from stock option exercises and other  Net cash provided by financing activities  1,980,465 Procease in cash and cash equivalents Cash and cash equivalents at beginning of period  (8,181) (8,181) (1,93,239 (4,937) 13,656 20,939  \$143,106  17.5%	Proceeds from issuance of senior notes	-	498,545		
Change in securities lending payable Common stock repurchases (7,203) (4,937) Tax benefit from stock-based compensation Proceeds from stock option exercises and other  Net cash provided by financing activities  1,980,465  1,980,465  1,740,304  193,239  (4,937) 13,656 20,939  \$143,106  17.5%	Debt issue costs	-	(3,825)		
Common stock repurchases  (7,203) (4,937)  Tax benefit from stock-based compensation Proceeds from stock option exercises and other  Net cash provided by financing activities  961,179 818,073 \$143,106 17.5%  Increase in cash and cash equivalents Cash and cash equivalents at beginning of period  1,740,304 732,016	Change in book overdraft	(3,959)	(8,181)		
Tax benefit from stock-based compensation Proceeds from stock option exercises and other  Net cash provided by financing activities  961,179  1,980,465  1,526,448  Cash and cash equivalents at beginning of period  14,554  13,656  20,939  \$143,106  17.5%	Change in securities lending payable	718,075	193,239		
Proceeds from stock option exercises and other  Net cash provided by financing activities  961,179  818,073  \$143,106  17.5%  Increase in cash and cash equivalents  Cash and cash equivalents at beginning of period  1,740,304  732,016	Common stock repurchases	(7,203)	(4,937)		
Net cash provided by financing activities  961,179  818,073  \$143,106  17.5%  Increase in cash and cash equivalents  1,980,465  1,526,448  Cash and cash equivalents at beginning of period  1,740,304  732,016	Tax benefit from stock-based compensation	14,554	13,656		
Increase in cash and cash equivalents  Cash and cash equivalents at beginning of period  1,980,465  1,526,448  732,016	Proceeds from stock option exercises and other	30,335	20,939		
Cash and cash equivalents at beginning of period 1,740,304 732,016	Net cash provided by financing activities	961,179	818,073	\$143,106	17.5%
	Increase in cash and cash equivalents	1,980,465	1,526,448		
Cash and cash equivalents at end of period \$3,720,769 \$2,258,464	Cash and cash equivalents at beginning of period	1,740,304	732,016		
	Cash and cash equivalents at end of period	\$3,720,769	\$2,258,464		

Six Months Ended June 30,

Humana Inc. Key Income Statement Ratios and Segment Operating Results Dollars in thousands

	Three Months End	led June 30,			Six Months En	ded June 30,		
				Percentage				Percentage
	2007	2006	Difference	Change	2007	2006	Difference	Change
Medical expense ratio								
Government Segment	84.3%	86.0%	-1.7%		86.7%	85.8%	0.9%	
Commercial Segment	80.7%	82.9%	-2.2%		80.1%	81.5%	-1.4%	
Consolidated	83.4%	85.1%	-1.7%		85.1%	84.4%	0.7%	
Selling, general, and administrative								
expense ratio								
Government Segment	10.0%	11.5%	-1.5%		10.4%	12.5%	-2.1%	
Commercial Segment	21.8%	18.7%	3.1%		21.2%	19.5%	1.7%	
Consolidated	13.0%	13.7%	-0.7%		13.2%	14.8%	-1.6%	
Detail of Pretax Income								
Government Segment	\$288,790	\$97,981	\$190,809	194.7%	\$306,655	\$119,553	\$187,102	156.5%
Commercial Segment	50,800	42,341	8,459	20.0%	145,156	151,977	(6,821)	-4.5%
Consolidated	\$339,590	\$140,322	\$199,268	142.0%	\$451,811	\$271,530	\$180,281	66.4%
Detail of Pretax Margins								
Government Segment	6.0%	2.6%	3.4%		3.3%	1.8%	1.5%	
Commercial Segment	3.1%	2.5%	0.6%		4.4%	4.5%	-0.1%	
Consolidated	5.3%	2.6%	2.7%		3.6%	2.7%	0.9%	

# Humana Inc. Membership Detail In thousands

	·							
	Ending		Ending	Year-over-year	Change	Ending	Sequential	Change
	June 30, 2007	Average - 2Q07	June 30, 2006	Amount	Percent	March 31, 2007	Amount	Percent
Medical Membership:								
Government Segment:								
Medicare Advantage - HMO	452.4	454.2	457.0	(4.6)	-1.0%	462.1	(9.7)	-2.1%
Medicare Advantage - PPO	66.9	66.5	64.6	2.3	3.6%	64.6	2.3	3.6%
Medicare Advantage - PFFS	614.4	611.9	438.2	176.2	40.2%	586.7	27.7	4.7%
Total Medicare Advantage	1,133.7	1,132.6	959.8	173.9	18.1%	1,113.4	20.3	1.8%
Medicare - PDP - Standard	2,131.0	2,133.1	2,066.5	64.5	3.1%	2,146.2	(15.2)	-0.7%
Medicare - PDP - Enhanced	1,075.9	1,075.2	977.2	98.7	10.1%	1,084.0	(8.1)	-0.7%
Medicare - PDP - Complete	233.2	235.7	415.1	(181.9)	-43.8%	243.5	(10.3)	-4.2%
Total Medicare stand-alone	0.440.4	0.444.0	0.450.0	(40.7)	0.50/	0.470.7	(00.0)	4.00/
PDPs	3,440.1	3,444.0	3,458.8	(18.7)	-0.5%	3,473.7	(33.6)	-1.0%
Total Medicare	4,573.8	4,576.6	4,418.6	155.2	3.5%	4,587.1	(13.3)	-0.3%
TRICARE insured	1,717.6	1,719.4	1,732.6	(15.0)	-0.9%	1,712.9	4.7	0.3%
TRICARE ASO	1,150.6	1,161.1	1,141.9	8.7	0.8%	1,165.5	(14.9)	-1.3%
Total TRICARE	2,868.2	2,880.5	2,874.5	(6.3)	-0.2%	2,878.4	(10.2)	-0.4%
Medicaid insured	384.9	384.0	418.5	(33.6)	-8.0%	384.0	0.9	0.2%
Medicaid ASO	182.7	181.7		182.7	100.0%	175.4	7.3	4.2%
Total Medicaid	567.6	565.7	418.5	149.1	35.6%	559.4	8.2	1.5%
Total Government Segment	8,009.6	8,022.8	7,711.6	298.0	3.9%	8,024.9	(15.3)	-0.2%
Commercial Segment:								
Fully-insured medical:								
Group	1,533.0	1,530.1	1,716.4	(183.4)	-10.7%	1,528.6	4.4	0.3%
Individual	205.0	200.3	170.0	35.0	20.6%	192.1	12.9	6.7%
Medicare supplement	8.3	7.8	6.7	1.6	23.9%	7.4	0.9	12.2%
Total fully-insured medical	1,746.3	1,738.2	1,893.1	(146.8)	-7.8%	1,728.1	18.2	1.1%
ASO	1,532.4	1,525.8	1,420.8	111.6	7.9%	1,529.4	3.0	0.2%
Total Commercial Segment	3,278.7	3,264.0	3,313.9	(35.2)	-1.1%	3,257.5	21.2	0.7%
Total medical membership	11,288.3	11,286.8	11,025.5	262.8	2.4%	11,282.4	5.9	0.1%
Specialty Membership (all Commercia	l Segment)	_						
Dental – fully-insured	978.1	979.9	955.6	22.5	2.4%	980.5	(2.4)	-0.2%
Dental - ASO	499.9	497.8	496.5	3.4	0.7%	503.7	(3.8)	-0.8%
Total dental	1,478.0	1,477.7	1,452.1	25.9	1.8%	1,484.2	(6.2)	-0.4%
Group life	439.8	439.2	427.2	12.6	2.9%	437.9	1.9	0.4%
Short-term disability	12.2	12.5	15.6	(3.4)	-21.8%	13.1	(0.9)	-6.9%
Total specialty membership	1,930.0	1,929.4	1,894.9	35.1	1.9%	1,935.2	(5.2)	-0.3%
		4						

# Premiums and Administrative Services Fees Detail

Dollars in thousands, except per member per month

					Per Member per	Month (A)
	Three Months End	led June 30,			Three Months End	ded June 30,
			Dollar	Percentage		
	2007	2006	Change	Change	2007	2006
Premium revenues						
Government Segment:						
Medicare Advantage	\$2,804,438	\$2,109,406	\$695,032	32.9%	\$825	\$792
Medicare stand-alone PDPs	1,051,259	801,755	249,504	31.1%	\$102	\$94
Total Medicare	3,855,697	2,911,161	944,536	32.4%		
TRICARE insured (B)	725,040	657,627	67,413	10.3%	\$141	\$127
Medicaid insured	132,486	129,158	3,328	2.6%	\$115	\$102
Total Government Segment premiums	4,713,223	3,697,946	1,015,277	27.5%		
Commercial Segment:						
Fully-insured medical	1,402,082	1,464,646	(62,564)	-4.3%	\$269	\$259
Specialty	107,945	101,883	6,062	5.9%	<b>\$22</b>	\$21
<b>Total Commercial Segment premiums</b>	1,510,027	1,566,529	(56,502)	-3.6%		
Total premium revenues	\$6,223,250	\$5,264,475	\$958,775	18.2%		
Administrative services fees						
TRICARE ASO (B)	\$15,535	\$11,144	\$4,391	39.4%	\$4	\$3
Medicaid ASO	2,136	-	2,136	100.0%	\$4	-
Total Government Segment	17,671	11,144	6,527	58.6%		
Commercial Segment	79,422	72,567	6,855	9.4%	\$13	\$13
Total administrative services fees	\$97,093	\$83,711	\$13,382	16.0%		

# Premiums and Administrative Services Fees Detail

Dollars in thousands, except per member per month

					Per Member per	Month (A)
	Six Months Ende	ed June 30,			Six Months Ended June 30,	
			Dollar	Percentage		
	2007	2006	Change	Change	2007	2006
Premium revenues						
Government Segment:						
Medicare Advantage	\$5,547,149	\$3,830,249	\$1,716,900	44.8%	\$828	\$808
Medicare stand-alone PDPs	1,957,685	1,316,912	640,773	48.7%	\$94	\$96
Total Medicare	7,504,834	5,147,161	2,357,673	45.8%		
TRICARE insured (B)	1,452,255	1,258,381	193,874	15.4%	\$141	\$121
Medicaid insured	261,811	258,625	3,186	1.2%	\$113	\$101
Total Government Segment premiums	9,218,900	6,664,167	2,554,733	38.3%		
Commercial Segment:						
Fully-insured medical	2,792,887	2,918,578	(125,691)	-4.3%	\$269	\$259
Specialty	216,026	203,216	12,810	6.3%	<b>\$22</b>	\$21
Total Commercial Segment premiums	3,008,913	3,121,794	(112,881)	-3.6%		
Total premium revenues	\$12,227,813	\$9,785,961	\$2,441,852	25.0%		
Administrative services fees						
TRICARE ASO (B)	\$29,829	\$22,335	\$7,494	33.6%	\$4	\$3
Medicaid ASO	4,232	<u>-</u> _	4,232	100.0%	\$4	-
Total Government Segment	34,061	22,335	11,726	52.5%		
Commercial Segment	158,896	140,054	18,842	13.5%	\$13	\$12
Total administrative services fees	\$192,957	\$162,389	\$30,568	18.8%		

Humana Inc.
Percentage of Ending Membership under Capitation Arrangements

	Government Segment					Commercial Segment			
June 30, 2007	Medicare Advantage	Medicare stand-alone PDPs	TRICARE	Medicaid	Total Govt. Segment	Fully- insured	ASO	Total Comm. Segment	Total Medical Membership
Capitated HMO hospital system based (C)	2.5%	-	_	_	0.3%	1.4%	_	0.8%	0.5%
Capitated HMO physician group based (C)	2.0%	-	-	26.0%	2.1%	1.5%	-	0.8%	1.8%
Risk-sharing (D)	24.3%	-	-	41.4%	6.4%	1.5%	-	0.8%	4.8%
All other membership	71.2%	100.0%	100.0%	32.6%	91.2%	95.6%	100.0%	97.6%	92.9%
Total medical membership	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
June 30, 2006									
Capitated HMO hospital system based (C)	3.4%	-	-	-	0.4%	1.8%	-	1.1%	0.6%
Capitated HMO physician group based (C)	2.5%	-	-	34.7%	2.2%	1.7%	-	1.0%	1.8%
Risk-sharing (D)	27.9%	-	-	64.6%	7.0%	2.3%	-	1.3%	5.3%
All other membership	66.2%	100.0%	100.0%	0.7%	90.4%	94.2%	100.0%	96.6%	92.3%
Total medical membership	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

# Detail of Medical and Other Expenses Payable Balance and Year-to-Date Changes

Dollars in thousands

Detail	Ωf	medical	and	other	expenses	navahla
Detail	OI	medicai	anu	otner	expenses	pavable

IBNR and other medical expenses payable (E) TRICARE IBNR (F)

TRICARE other medical expenses payable (G) Unprocessed claim inventories (H)

Processed claim inventories (I)

Payable to pharmacy benefit administrator (J)

Total medical and other expenses payable

June 30, 2007	March 31, 2007	December 31, 2006
\$2,028,722	\$1,869,209	\$1,686,051
308,112	361,786	318,583
100,975	97,994	94,699
211,300	222,300	218,400
142,171	135,241	115,424
162,866	199,684	55,104
\$2,954,146	\$2,886,214	\$2,488,261

# Year-to-date changes in medical and other expenses payable

Balances at January 1

Acquisitions

Incurred related to:

Current year (K)

Prior years - non-TRICARE (K)

Prior years - TRICARE (L)

Total incurred

Paid related to:

Current year

Prior years

Total paid

Balances at end of period

Six Months Ended June 30, 2007	Three Months Ended March 31, 2007	Year Ended December 31, 2006
\$2,488,261	\$2,488,261	\$1,909,682
-	-	21,198
10,574,111	5,370,722	17,696,654
(156,032)	(148,777)	(178,998)
(13,661)	(7,945)	(96,452)
10,404,418	5,214,000	17,421,204
(8,275,133)	(3,800,981)	(15,532,079)
(1,663,400)	(1,015,066)	(1,331,744)
(9,938,533)	(4,816,047)	(16,863,823)
\$2,954,146	\$2,886,214	\$2,488,261

# Humana Inc. Medical Claims Reserves Statistics

### Receipt Cycle Time (M)

1st Quarter Average 2nd Quarter Average 3rd Quarter Average 4th Quarter Average Full Year Average

2007	2006	Change	Percentage Change
15.6	16.1	(0.5)	-3.1%
15.6	15.8	(0.2)	-1.3%
-	16.0	N/A	N/A
-	15.8	N/A	N/A
15.6	15.9	(0.3)	-1.9%

### **Unprocessed Claims Inventories**

Date	Estimated Valuation (000's)	Claim Item Counts	Number of Days on Hand
6/30/2005	\$119,500	443,600	4.0
9/30/2005	\$136,700	512,800	4.7
12/31/2005	\$148,200	498,400	4.6
3/31/2006	\$185,300	683,900	5.6
6/30/2006	\$193,700	702,000	4.8
9/30/2006	\$187,900	623,900	5.4
12/31/2006	\$218,400	757,700	6.1
3/31/2007	\$222,300	747,200	5.5
6/30/2007	\$211,300	751,600	4.9

# Humana Inc. Medical Claims Reserves Statistics (Continued)

### Days in Claims Payable (N)

Quarter Ended	Days in Claim Payable (DCP)	Annual Change	Percentage Change	DCP Excluding Capitation	Annual Change	Percentage Change
6/30/2005	52.8	5.4	11.4%	58.6	4.5	8.3%
9/30/2005	54.0	2.2	4.2%	60.8	1.7	2.9%
12/31/2005	60.3	10.8	21.8%	66.6	11.8	21.5%
3/31/2006	59.1	8.6	17.0%	65.5	9.4	16.8%
6/30/2006	59.5	6.7	12.7%	65.5	6.9	11.8%
9/30/2006	61.2	7.2	13.3%	67.1	6.3	10.4%
12/31/2006	60.2	(0.1)	-0.2%	66.5	(0.1)	-0.2%
3/31/2007	62.0	2.9	4.9%	67.8	2.3	3.5%
6/30/2007	62.4	2.9	4.9%	69.7	4.2	6.4%

### **Year-to-Date Change in Days in Claims Payable** (O) (P)

### DCP - 4th quarter of prior year

Components of year-to-date change in DCP:

Change in claims receipt cycle time

Change in unprocessed claims inventories

Change in processed claims inventories

Change in TRICARE reserve balances

Change in pharmacy payment cutoff

Change in provider payables under risk arrangements

All other

### **DCP - current quarter**

2007	2006
60.2	60.3
(8.0)	(1.6)
(0.2)	1.7
0.6	0.8
(0.1)	(2.1)
-	(1.3)
2.5	1.9
0.2	0.5
62.4	60.2

Footnotes to Statistical Schedules and Supplementary Information

2Q07 Earnings Release

#### **Footnote**

- (A) Computed based on average membership for the period (i.e., monthly ending membership during the period divided by the number of months in the period).
- (B) TRICARE revenues are not contracted on a per-member basis.
- In a limited number of circumstances, the company contracts with hospitals and physicians to accept financial risk for a defined set of HMO membership. In transferring this risk, the company prepays these providers a monthly fixed-fee per member to coordinate substantially all of the medical care for their capitated HMO membership, including some health benefit administrative functions and claims processing. For these capitated HMO arrangements, the company generally agrees to reimbursement rates that target a medical expense ratio. Providers participating in hospital-based capitated HMO arrangements generally receive a monthly payment for all of the services within their system for their HMO membership. Providers participating in physician-based capitated HMO arrangements generally have subcontracted specialist physicians and are responsible for reimbursing such physicians and hospitals for services rendered to their HMO membership.
- (D) In some circumstances, the company contracts with physicians under risk-sharing arrangements whereby physicians have assumed some level of risk for all or a portion of the medical costs of their HMO membership. Although these arrangements do include capitation payments for services rendered, the company processes substantially all of the claims under these arrangements.
- (E) IBNR represents an estimate of medical expenses payable for claims incurred but not reported (IBNR) at the balance sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i.e. a shorter time span results in lower reserves for claims IBNR). Other medical expenses payable includes amounts payable to providers under capitation arrangements.
- (F) TRICARE IBNR primarily fluctuates due to medical expense inflation and changes in the utilization of benefits.
- (G) TRICARE other medical expenses payable may include liabilities to subcontractors and/or risk share payables to the Department of Defense. The level of these balances may fluctuate from period to period due to the timing of payment (cutoff) and whether or not the balances are payables or receivables (receivables from the Department of Defense are classified as receivables in the company's balance sheet).
- (H) Unprocessed claim inventories represent the estimated valuation of claims received but not yet fully processed. TRICARE claim inventories are not included in this amount as an independent third party administrator processes all TRICARE medical claims on the company's behalf. Reserves for TRICARE unprocessed claims inventory are included in TRICARE IBNR.
- (I) Processed claim inventories represent the estimated valuation of processed claims that are in the post-claim-adjudication process, which consists of administrative functions such as audit and check batching and handling.
- (J) The balance due to the company's pharmacy benefit administrator fluctuates as a result of the number of business days in the last payment cycle of the month. Payment cycles are every 10 days (10th & 20th of month) and the last day of the month.
- (K) Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development). There were no changes in the approach used to determine our estimate of claim reserves during the quarter.
- (L) Changes in estimates of TRICARE incurred claims for prior years result primarily from claim costs and utilization levels developing favorably from the levels originally estimated for the second half of the prior year. As a result of substantial risk-sharing provisions with the Department of Defense and with subcontractors, any resulting impact on operations from the change in estimates of incurred related to prior years is substantially reduced, whether positive or negative.
- (M) The receipt cycle time measures the average length of time between when a claim was initially incurred and when the claim form was received. Receipt cycle time data for our largest claim processing platforms represents 70% to 75% of the company's fully-insured claims volume. Pharmacy claims are excluded from this measurement.
- (N) A common metric for monitoring medical claim reserve levels relative to the medical claims expense is days in claims payable, or DCP, which represents the medical claim liabilities at the end of the period divided by average medical expenses per day in the quarterly period. Since the company has some providers under capitation payment arrangements (which do not require a medical claim IBNR reserve), the company has also summarized this metric excluding capitation expense. In addition, this calculation excludes the impact of the company's stand-alone PDP business.
- Excludes the impact of Medicare stand-alone PDPs.
- (P) DCP fluctuates due to a number of issues, the more significant of which are detailed in the rollforward of DCP from the fourth quarter of the prior year. Growth in certain product lines can also impact DCP for the quarter since a provision for claims would not have been recorded for members that had not yet enrolled earlier in the quarter, yet those members would have a provision and corresponding reserve recorded upon enrollment later in the quarter.